Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

Completed · Phase 2

Conditions studied: Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer

In brief

This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.

Key facts

Study ID

NCT00064025

Run by

Gynecologic Oncology Group

People needed

75

Starts

2004-04-01

Last updated by the study team

2016-04-11

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed primary endometrioid adenocarcinoma of the uterine corpus
• All histologic grades and stages eligible
• Diagnosis by endometrial curettage or biopsy within the past 8 weeks
• Must have the initial tissue block or 16 unstained sections of 5 micron thickness available
• Performance status - GOG 0-3
• No history of thrombophlebitis or thromboembolic disorders
• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• No prior therapeutic progesterone or anti-estrogen therapy within 3 months before diagnosis
• No concurrent aminoglutethimide
• No prior cancer treatment that would preclude study therapy
• No concurrent bosentan
• No concurrent rifampin

Where it is running

• Gynecologic Oncology Group — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.